



Myrexis to Present at Piper Jaffray Health Care Conference

SALT LAKE CITY, Nov. 18, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, is scheduled to present an overview of the Company at the Piper Jaffray Health Care Conference, taking place November 30 and December 1, 2010.

Dr. Hobden and Robert Lollini, Chief Financial Officer and Treasurer, will be available to participate in one-on-one meetings with investors attending the conference.

Event: 22nd Annual Piper Jaffray Health Care Conference

Date: Wednesday, December 1, 2010

Time: 2:30pm ET

Place: The New York Palace Hotel, New York City

The presentation will be audio webcast live and can be accessed by visiting the investor relations section of Myrexis' website at www.myrexis.com. The webcast will be archived for 90 days.

About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a robust pipeline of clinical and pre-clinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomics, drug discovery and clinical and commercial development.

The Company's oncology pipeline is led by [Azixa](#) (verubulin, MPC-6827), a novel small molecule microtubule destabilizing agent in Phase 2 clinical development for the treatment of brain cancers. Additional novel, potent, small molecule oncology compounds include [MPC-3100](#), a fully-synthetic inhibitor of Hsp90 in Phase 1; and [MPC-9528](#), a Cancer Metabolism Inhibitor (CMI) in IND-enabling studies. Myrexis is also evaluating [MPI-0485520](#), an orally bioavailable, potent and selective small molecule inhibitor of type I interferon production that is being developed for cancer and chronic inflammation.

For more information, please visit www.myrexis.com.

Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6327>

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the scheduled presentation of an overview of the Company at the Piper Jaffray Health Care Conference, taking place November 30 and December 1, 2010. These risks and uncertainties include, but are not limited to: the risk that we may be unable to further identify, develop and achieve commercial success for new products and technologies; the risk that we may be unable to discover drugs that are safer and more efficacious than our competitors; the risk that we may be unable to develop and maintain manufacturing capabilities for our products; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we may be unable to protect our proprietary technologies; the risk of patent-infringement claims; risks of new, changing and competitive technologies and regulations in the

United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.

Patrick M. Burke, Ph.D., V.P., Corporate and

Business Development

801-214-7822

investor.relations@myrexis.com

The Ruth Group

Investors

Sara Pellegrino

(646) 536-7002

spellegrino@theruthgroup.com

Media

Jason Rando

(646) 536-7025

jrando@theruthgroup.com